Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 91-98

  Klasa Mazurkiewicz, Dagmara ^a   Narkiewicz, Joanna ^b   Milczek, Tomasz ^a   Lipińska, Barbara ^b   Emerich, Janusz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Maspin; Ovarian cancer; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; MASPIN; PACLITAXEL;

ADULT; AGED; ARTICLE; ASCITES; BENIGN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; FEMALE; HUMANS; KRUKENBERG TUMOR; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SERPINS; YOUNG ADULT;

EID: 62549142221     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.038     Document Type: Article

References (48)

1. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 329 (1993) 1550-1559
2. Friedlander M.L. Prognostic factors in ovarian cancer. Semin Oncol 25 (1998) 305-314
3. Fader A.N., and Rose P.G. Role of surgery in ovarian carcinoma. J Clin Oncol 25 (2007) 2873-2883
4. Bristow R.E., Tomacruz R.S., Armstrong D.K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
5. Ono K., Tanaka T., Tsunoda T., et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60 (2000) 5007-5011
6. Spentzos D., Levine D.A., Ramoni M.F., et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22 (2004) 4700-4710
7. Zou Z., Anisowicz A., Hendrix M.J., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
8. Schneider S.S., Schick C., Fish K.E., et al. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci U S A 92 (1995) 3147-3151
9. Maass N., Hojo T., Zhang M., et al. Maspin - a novel protease inhibitor with tumor-suppressing activity in breast cancer. Acta Oncol 39 (2000) 931-934
10. Sheng S., Carey J., Seftor E.A., et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 93 (1996) 11669-11674
11. Zou Z., Zhang W., Young D., et al. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of maspin expression by androgen ablation. Clin Cancer Res 8 (2002) 1172
12. Ito R., Nakayama H., Yoshida K., et al. Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncol Rep 12 (2004) 985-990
13. Maass N., Hojo T., Ueding M., et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 7 (2001) 812-817
14. Kashima K., Ohike N., Mukai S., et al. Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas. Hepatobiliary Pancreat Dis Int 7 (2008) 86-90
15. Smith S.L., Watson S.G., Ratschiller D., et al. Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene 22 (2003) 8677-8687
16. Shams T.M., Samaka R.M., and Shams M.E. Maspin protein expression: a special feature of papillary thyroid carcinoma. J Egypt Natl Cancer Inst 18 (2006) 274-280
17. Li H.W., Leung S.W., Chan C.S., et al. Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep 17 (2007) 393-398
18. Abraham S., Zhang W., Greenberg N., et al. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol 169 (2003) 1157-1161
19. Blacque O.E., and Worrall D.M. Evidence for a direct interaction between the tumor suppressor serpin, maspin, and types I and III collagen. J Biol Chem 277 (2002) 10783-10788
20. Cella N., Contreras A., Latha K., et al. Maspin is physically associated with β1 integrin regulating cell adhesion in mammary epithelial cells. FASEB J 20 (2006) 1510-1512
21. Zhang W., Shi H.Y., Zhang M., et al. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 5 (2005) 50
22. Latha K., Zhang W., Cella N., et al. Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol 25 (2005) 1737-1748
23. Zhang M., Volpert O., Shi Y.H., et al. Maspin is an angiogenesis inhibitor. Nat Med 6 (2000) 196-199
24. Cher M.L., Biliran Jr. H.R., Bhagat S., et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci 100 (2003) 7847-7852
25. Solomon L.A., Munkarah A.R., Schimp V.L., et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 101 (2006) 385-389
26. Zou Z., Gao C., Nagaich A.K., et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275 (2000) 6051-6054
27. Khalkhali-Ellis Z. Maspin: the new frontier. Clin. Cancer Res. 12 (2006) 7279-7283
28. Rose S.L., Fitzgerald M.P., White N.O., et al. Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol 102 (2006) 319-324
29. Sood A.K., Fletcher M.S., Gruman L.M., et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8 (2002) 2924-2932
30. Secord A.A., Lee P.S., Darcy K.M., et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol 101 (2006) 390-397
31. Surowiak P., Materna V., Drag-Zalesinska M., et al. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol 25 (2006) 131-139
32. Abd El-Wahed M.M. Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Cancer Inst 17 (2005) 173-183
33. Pemberton P.A., Tipton A.R., Pavloff N., et al. Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J Histochem Cytochem 45 (1997) 1697-1706
34. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
35. Pierson C.R., McGowen R., Grignon D., et al. Maspin is up-regulated in premalignant prostate epithelia. Prostate 53 (2002) 255-262
36. Yu M., Zheng H., Tsuneyama K., et al. Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression. Hum Pathol 38 (2007) 1248-1255
37. Xia W., Lau Y.K., Hu M.C., et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 19 (2000) 2398-2403
38. Boltze C. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol Res Pract 200 (2005) 783-790
39. Umekita Y., Ohi Y., Sagara Y., et al. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 100 (2002) 452-455
40. Mohsin S.K., Zhang M., Clark G.M., et al. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199 (2003) 432-435
41. Hirai K., Koizumi K., Haraguchi S., et al. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg 79 (2005) 248-253
42. Lee D.Y., Park C.S., Kim H.S., et al. Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol 16 (2008) 13-18
43. McKenzie S., Sakamoto S., and Kyprianou N. Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene (2008) 1-9
44. Bolat F., Gumurdulu D., Erkanli S., et al. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathol Res Pract 204 (2008) 379-387
45. Marioni G., Koussis H., Gaio E., et al. MASPIN's prognostic role in patients with advanced head and neck carcinoma treated with primary chemotherapy (carboplatin plus vinorelbine) and radiotherapy: preliminary evidence. Acta Oto-laryngol 25 (2008) 1-7
46. Surowiak P. Prediction of the response to chemotherapy in ovarian cancers. Folia Morphol 65 (2006) 285-294
47. Watanabe Y., Ueda H., Etoh T., et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res 27 (2007) 1449-1452
48. Balch C., Huang T.H., Brown R., and Nephew K.P. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191 (2004) 1552-1572